Total numbers of differentially expressed genes with B values > 0
| Hybridization comparison . | Days after treatment . | ||
|---|---|---|---|
| D2 . | D3 . | D5 . | |
| HIV-1/mock (representing HIV binding, entry, and replication) | 4 | 52 | 126 |
| AT2-HIV-1/mock (representing HIV binding and entry) | 0 | 3 | 14 |
| HIV-1/AT2-HIV-1 (replication) | 3 | 41 | 98 |
| Hybridization comparison . | Days after treatment . | ||
|---|---|---|---|
| D2 . | D3 . | D5 . | |
| HIV-1/mock (representing HIV binding, entry, and replication) | 4 | 52 | 126 |
| AT2-HIV-1/mock (representing HIV binding and entry) | 0 | 3 | 14 |
| HIV-1/AT2-HIV-1 (replication) | 3 | 41 | 98 |
MDMs were mock, or AT2-HIV-1 or HIV-1 treated. RNA harvested at 2, 3, or 5 days after treatment was used for microarray hybridization between the groups. Only genes with B values > 0 were selected as being most significantly differentially expressed.